Contact Us
Drug Search Results
More Filters [+]

Asunaprevir

Alternative Names: asunaprevir, bms-650032, sunvepra
Latest Update: 2024-03-01
Latest Update Note: PubMed Publication

Product Description

Asunaprevir is an orally bioavailable inhibitor of the nonstructural protein 3 (NS3), with potential activity against hepatitis C virus (HCV).  (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Asunaprevir)

Mechanisms of Action: HCV-NS3/4A Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Canada | Chile | Colombia | Japan | Korea | New Zealand | Peru | Russia | Taiwan | Turkey

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Asunaprevir

Countries in Clinic: China, Unknown Location

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Hepatitis C, Chronic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CTR20132226

P3

Active, not recruiting

Hepatitis C, Chronic

None

CTR20132850

P3

Active, not recruiting

Hepatitis C, Chronic

None

Recent News Events

Date

Type

Title

03/01/2024

PubMed

 The Role of CYPs and Transporters in the Biotransformation and Transport of the Anti-hepatitis C Antiviral Agents Asunaprevir, Daclatasvir, and Beclabuvir: Impact of Liver Disease, Race and Drug-drug Interactions on Safety and Efficacy.

02/22/2024

News Article

 Atomic AI Announces Appointments of New Independent Member to its Board of Directors and Additions to the Scientific Advisory Board

02/14/2024

PubMed

 Impacts of humic substances, elevated temperature, and UVB radiation on bacterial communities of the marine sponge Chondrilla sp.

01/24/2024

PubMed

 HCV antiviral drugs have the potential to adversely perturb the maternal-fetal communication axis through inhibition of CYP3A7 DHEA-S oxidation.

02/28/2023

News Article

 Revance Adds Experienced Pharmaceutical Executive to Board of Directors with Appointment of Dr. Vlad Coric, M.D., as Independent Director

04/11/2022

News Article

 Lucy Therapeutics Receives $4.9 Million Grant from Michael J. Fox Foundation

06/07/2019

News Article

 Japan Pharma, Healthcare, Regulatory and Reimbursement Landscape 2019-2020 - ResearchAndMarkets.com

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions